MENU
Showcases Stock ranks Forex

Sangamo Therapeutics (SGMO)
5.29  0.09 (1.73%) 08-08 16:00
Open: 5.23 Pre. Close: 5.2
High: 5.355 Low: 5.121
Volume: 1,416,411 Market Cap: 828M
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 5.367 - 5.387 5.387 - 5.403
Low: 5.067 - 5.092 5.092 - 5.112
Close: 5.252 - 5.291 5.291 - 5.322
Stock Technical Analysis
Overall:     
Target: Six months: 6.25
One year: 7.31
Support: Support1: 4.61
Support2: 4.15
Resistance: Resistance1: 5.36
Resistance2: 6.25
Pivot: 4.64
Moving Averages: MA(5): 4.90
MA(20): 4.61
MA(100): 4.53
MA(250): 6.57
MACD: MACD(12,26): 0.17
Signal(12,26,9): 0.11
%K %D: %K(14,3): 85.60
%D(3): 72.55
RSI: RSI(14): 70.09
52-Week: High: 11.49
Low: 3.12
Change(%): -44.5
Average Vol(K): 3-Month: 1798
10-Days: 1427
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ SGMO ] has closed above the upper band by 6.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 1.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Thu, 04 Aug 2022
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

Sun, 24 Jul 2022
DekaBank Deutsche Girozentrale Buys 7000 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

Thu, 21 Jul 2022
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation - Yahoo Finance

Fri, 06 May 2022
Sangamo Therapeutics stock slips despite Q1 (NASDAQ:SGMO) - Seeking Alpha

Mon, 02 May 2022
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Business Wire

Thu, 21 Apr 2022
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Business Wire

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 146.69
Shares Float (M) 121.99
% Held by Insiders 16.91
% Held by Institutions 55.72
Shares Short (K) 10320
Shares Short Prior Month (K) 10500
Stock Financials
EPS -1.210
Book Value (p.s.) 2.280
Profit Margin -156.53
Operating Margin -161.82
Return on Assets (ttm) -14.9
Return on Equity (ttm) -43.9
Qtrly Rev. Growth 7.4
Gross Profit (p.s.) -0.819
Sales Per Share 0.768
EBITDA (p.s.) -1.172
Qtrly Earnings Growth
Operating Cash Flow (M) -223.68
Levered Free Cash Flow (M) -93.14
Stock Valuation
PE Ratio -4.37
PEG Ratio
Price to Book value 2.32
Price to Sales 6.89
Price to Cash Flow -3.47
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android